Abstract
Early postpartum hemorrhage remains a significant cause of maternal morbidity and mortality. Postpartum hemorrhage is most commonly due to uterine atony and often responds to medical treatments such as administration of uterotonic drugs, alone or in combination with uterine massage or bimanual compression. As the incidence of cesarean section continues to rise, the problem of placenta previa and accreta is likely to become more common. For first-line management of postpartum hemorrhage adequate blood and fluid replacement is mandatory. In recent years new therapeutic measures to control the bleeding have gained attention. Although, these newer therapies focus on avoiding the need for emergency hysterectomy and preservation of reproductive function, reports of subsequent pregnancies are still scarce. Established management options are shortly reviewed and novel medical and surgical treatments are more extensively discussed.
Keywords: postpartum hemorrhage, atony, recombinant activated factor VII, tranexamic acid
Current Pharmaceutical Design
Title: Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Volume: 11 Issue: 6
Author(s): F. W. Bouwmeester, A. C. Bolte and H. P. van Geijn
Affiliation:
Keywords: postpartum hemorrhage, atony, recombinant activated factor VII, tranexamic acid
Abstract: Early postpartum hemorrhage remains a significant cause of maternal morbidity and mortality. Postpartum hemorrhage is most commonly due to uterine atony and often responds to medical treatments such as administration of uterotonic drugs, alone or in combination with uterine massage or bimanual compression. As the incidence of cesarean section continues to rise, the problem of placenta previa and accreta is likely to become more common. For first-line management of postpartum hemorrhage adequate blood and fluid replacement is mandatory. In recent years new therapeutic measures to control the bleeding have gained attention. Although, these newer therapies focus on avoiding the need for emergency hysterectomy and preservation of reproductive function, reports of subsequent pregnancies are still scarce. Established management options are shortly reviewed and novel medical and surgical treatments are more extensively discussed.
Export Options
About this article
Cite this article as:
Bouwmeester W. F., Bolte C. A. and van Geijn P. H., Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage, Current Pharmaceutical Design 2005; 11 (6) . https://dx.doi.org/10.2174/1381612053381882
DOI https://dx.doi.org/10.2174/1381612053381882 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models
Current Pharmaceutical Biotechnology Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Application of Hematopoietic Cells to Therapeutic Angiogenesis
Current Pharmaceutical Design Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Sulfonylureas
Current Drug Safety Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy